Eyes on July 2026: Approvals, pipeline momentum, and AI take center stage

Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.

LUGANO missed its visual noninferiority endpoint for the vorolanib insert vs aflibercept in nAMD despite comparable anatomic control. Regillo attributes the gap partly to 9 outliers with vision loss unrelated to nAMD.

Noab Banoub, a third year medical student, describes his journey into medicine and his view of ophthalmology's future.

In the latest episode of The Wills Retina Report, Regillo and Ho discuss where gene therapy stands for retinal disease, from late-stage programs in neovascular age-related macular degeneration to earlier efforts in geographic atrophy and diabetic retinopathy.

Patients with atrial fibrillation (AF) had measurable structural retinal changes in a large international study.

IRIS Registry data showed no change in anti-VEGF frequency, vision, or retinal thickness after patients with DME began a GLP-1RA.

In the latest episode of The Retina TL;DR with Dr. Weng—Part 2 of a special two-part series—host Christina Y. Weng, MD, MBA, FASRS, sits down with two more of her former residents for candid advice on transitioning into fellowship, balancing research and family, and what excites them most about the future of retina.

Spectacle lenses with highly aspherical lenslets are safe and effective for reducing myopia progression in US children.